Two consecutive boards three live national health: cooperation with Pfizer project still needs to go through internal decision-making procedures and regulatory approvals.

On the evening of May 20th, Sanliv Health announced in a public statement that the 707 Project, a dual-specific antibody product that targets both PD-1 and VEGF developed in partnership with Pfizer, still needs to go through necessary internal decision-making processes and obtain approval from the authorized regulatory agencies before it can be officially implemented. There are uncertainties in the implementation process. The price deviation of the company's stock trading for two consecutive trading days has cumulatively exceeded 30%, which falls under the category of abnormal stock trading fluctuations according to relevant regulations.